gynaecological cancer

News

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

News

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo

News

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ImmunoGen, Inc.

Views & Analysis

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovatio...

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100%

Corcept gets FDA OK for first-in-class ovarian cancer drug

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovatio...

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

gynaecological cancer

Editor's Picks